Sublingual Immunotherapy With House Dust Mite Extract in Asthmatic Children
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00172341|
Recruitment Status : Unknown
Verified July 2004 by National Taiwan University Hospital.
Recruitment status was: Not yet recruiting
First Posted : September 15, 2005
Last Update Posted : November 3, 2005
Asthma, the airway inflammatory disorder, is an important chronic disease in children. About 10~15% children are bothered with this. Allergens, such as house-dust mites (HDM), animal dander (i.e. cats and dogs), and seasonal pollens, are often implicated as causative and triggering factors of respiratory attacks in children with asthma. Among them, mites are the most common indoor allergen associated with asthma worldwide.
It appears that SLIT is somewhat effective and safe. However, on the current evidence, further studies are needed to define the indications, the duration of treatment and therapeutic optimal dose of standardized allergen extracts in relation to efficacy and side effects before it is recommended for routine clinical use. The objective of the present study was to investigate the effects and safety of StaloralTM, the standardized extracts of D. pt. and D. f., in asthmatic children allergic to HDM.
|Condition or disease||Intervention/treatment||Phase|
|Asthma||Drug: Staloral TM||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Efficacy and Safety of Sublingual Immunotherapy With House Dust Mite Extract in Asthmatic Children: A Double-Blind, Randomized, and Placebo-Controlled Study|
- Change of asthmatic scores from baseline
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00172341
|Contact: Li-Chieh Wang, MD||886-2-23123456 ext firstname.lastname@example.org|
|Principal Investigator:||Li-Chieh Wang, MD||National Taiwan University Hospital|